文献リスト

1) Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimerʼs disease. Lancet. 1976; 2: 1403

2) Bowen DM, Smith CB, White P, et al. Neuro-transmitter-related enzymes and indices of hypo-xia in senile dementia and other abiotrophies. Brain. 1976; 99: 459-96

3) Geula C, Mesulam MM. Systematic regional variations in the loss of cortical cholinergic fibers in Alzheimerʼs disease. Cereb Cortex. 1996; 6: 167-77

4) Whitehouse PJ, Price DL, Clark AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981; 10: 122-6

5) Shimohama S, Taniguchi T, Fujiwara M, et al. Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J Neurochem. 1986; 46: 288-93

6) Whitehouse P, Martino AM, Antuono PG, et al. nicotinic acetylcholine binding sites in Alzheimerʼs disease. Brain Res. 1986; 371: 146-51

7) Kadir A, Darreh-Shori T, Almkvist O, et al. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging. 2008; 29: 1204-17

8) 鍋島俊隆. アセチルコリンエステラーゼ阻害薬の薬理学的特性—ガランタミンを中心として. Cognition and Dementia. 2011; 10 Suppl 1: 24-9

9) 下濱 俊. ニコチン性アセチルコリン受容体を介したアルツハイマー病の新しい治療—Nicotinic APL (allosteric potentiating ligand) による神経保護作用とガランタミン. 老年精神医学雑誌. 2004; 15: 1077-90

10) Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimerʼs disease. Dement Geriatr Cogn Disord. 2000; 11 Suppl 1: 11-8

11) Arias E, Ales E, Gabilan NH, et al. Galantamine prevents apoptosis induced by β-amyloid and thapsigargin: involvement of nicotinic acety-lcholine receptors. Neuropharmacology. 2004; 46: 103-14

12) Kihara T, Sawada H, Nakamizo T, et al. Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity. Biochem Biophys Res Commun. 2004; 325: 976-82

13) Takata K, Kitamura Y, Saeki M, et al. Galantamine-induced amyloid-β clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem. 2010; 285: 40180-91

14) 本間 昭, 中村 祐, 斎藤隆行, 他. ガランタミン臭化水素酸塩のアルツハイマー型認知症に対するプラセボ対照二重盲検比較試験. 老年精神医学. 2011; 22: 333-44

15) Wilcock G, Howe I, Coles H, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimerʼs disease. Drugs Aging. 2003; 20: 777-89

16) Herrmann N, Rabheru K, Wang J, et al. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry. 2005; 13: 527-34

17) Davis B, Sadic K. Circadian cholinergic rhythms: implication for cholinesterase inhibitor therapy. Dement Geriatr Cogn Disorder. 2006; 21: 120-9

18) 繁田雅弘. 海外データからみたガランタミンの中核症状に対する効果と安全性. 老年精神医学雑誌. 2011; 22 増刊号II: 40-4

19) Wimo A, Winblad B, Shah SN, et al. Impact of donepezil treatment for Alzheimerʼs disease on caregiver time. Curr Med Res Opin. 2004; 20: 1221-5

20) Blesa R. Galantamine: therapeutic effects beyond cognition. Dement Geriatr Cogn Disord. 2000; 11: 28-34

21) 下濱 俊. アルツハイマー病の治療—現状と解決すべき諸問題. 日本薬理学会誌. 2008; 131: 351-6

22) Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci. 2003; 4: 131-8

23) Eskander MF, Nagykery NG, Leung EY, et al. Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimerʼs plaques and tangles. Brain Res. 2006; 1060: 144-52

24) 赤池昭紀, 久米利明. ニコチン受容体サブタイプと生体機能: 新しい創薬ターゲット. 医学のあゆみ. 2004; 210: 687-90

25) Bailey JA, Lahiri DK. A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fatal rat primary cortical neurons and its implication in Alzheimerʼs disease. J Neurochem. 2010; 112: 843-53

26) Zhou X, Patel AR, Perez F, et al. Acetyl-choliesterase inhibitor rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines. Transl Res. 2009; 153: 132-41

27) Shanks M, Kivipelto M, Bullock R, et al. Cholinesterase inhibition; Is there evidence for disease-modifying effects？ Curr Med Res Opin. 2009; 25: 2439-46

28) Nakamura Y, Imai Y, Shigeta M, et al. A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanes patients with Alzheimerʼs disease. Dement Geriatr Cogn Disord Extra. 2011; 1: 163-79

29) Winblad B, Grossberg G, Frolich L, et al. IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007; 69 Suppl 1: S14-22

30) Blesa R, Ballard C, Orgogozo J-M, et al. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology. 2007; 69 Suppl 1: S23-8

31) Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moder-ate to moderately-severe Alzheimerʼs disease over a 2-year period. Curr Med Res Opin. 2005; 21: 1317-27

32) Ninomiya H, Fukunaga R, Taniguchi T, et al. [3H]N-[1-(2-thienyl) cyclohexyl]-3, 4-piperidine ([3H]TCP) binding in human frontal cortex: decreases in Alzheimer-type dementia. J Neurochem. 1990; 54: 526-32

33) Danysz W, Parsons CG, Mobius HJ, et al. neuroprotective and symptomatological action of memantine relevant for Alzheimerʼs disease- a unified glutamatergic hypothesis on the mecha-nism of action. Neurotox Res. 2000; 2: 85-97

34) Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist- a review of preclical data. Neuropharmacology. 1999; 38: 735-67

35) Cowburn RF, Wiehager B, Trief E, et al. Effects of β-amyloid(25-35) peptides on radioligand binding to excitatory amino acid receptors and voltage-dependent calcium channels: evidence for a selective affinity for the glutamate and glycine recognition sites of the NMDA receptor. Neurochem Res. 1997; 22: 1437-42

36) Le W-D, Colom LV, Xie W-J, et al. Cell death induced by β-amyloid 1-40 in MES 23. 5 hybrid clone: the role of nitric oxide and NMDA-gated channel activation leading to appoptosis. Brain Res. 1995; 686: 49-60

37) Lacor PN, Buwel MC, Furlow PW, et al. Abeta oligomer-induced aberrations in synapse com-position, shape, and density provide a molecular basis for loss of connectivity in Alzheimerʼs disease. J Neurosci. 2007; 27: 796-807

38) Decker H, Lo KY, Unger SM, et al. Amyloid-beta peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mecha-nism that is mediated by glycogen synthase kinase 3beta in primary cultured hippocampal neurons. J Neurosci. 2010; 30: 9166-71

39) Scholtzova H, Wadghiri YZ, Douadi M, et al. Memantine leads to behavioral improvement and amyloid reduction in Alzheimerʼs-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res. 2008; 86: 2784-91

40) Martinez-Coria H, Green KN, Billings LM, et al. Memantine improves cognition and reduces Alzheimerʼs-like neuropathology in transgenic mice. Am J Pathol. 2010; 176: 870-80

41) 中村 祐, 本間 昭, 北村 伸, 他. 新規NMDA受容体拮抗剤であるメマンチン塩酸塩の中等度から高度アルツハイマー型認知症に対する第III相試験-有効性および安全性の検討-. 老年精神医学雑誌. 2011; 22: 464-73

42) 中村 祐, 認知症治療で期待される新薬. 日病薬誌. 2011; 47: 1015-9

43) Raina P, Santaquida P, Ismalla A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008; 148: 379-97

44) Schmitt FA, van Dyck CH, Wichems CH, et al. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory. Alzheimer Dis Assoc Disord. 2006; 20: 255-62

45) Cummings JL, Schneider E, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006; 67: 57-63

46) Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004; 291: 317-24

47) Maidment ID, Fox CG, Boustani M, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Ann Pharmacother. 2008; 42: 32-8

48) Jones RW. A review comparing the safety and tolerability of memantine with the acetyl-cholinesterase inhibitors. Int J Geriatr Psychiatry. 2010; 25: 547-53

49) Farlow MR, Cummings JL. Effective phar-macologic management of Alzheimerʼs disease. Am J Med. 2007; 120: 388-97

50) Grossberg GT, Edwards KR, Zhao Q. Rationale for combination therapy with galantamine and memantine in Alzheimerʼs disease. J Clin Pharmacol. 2006; 46: 17-26

51) Dantoine T, Auriacombe S, Sarazin M, et al. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimerʼs disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract. 2006; 60: 110-8

52) Farlow MR, Alva G, Meng X, et al. A 25-week, open-label trial investigating rivastigmine trans-dermal patches with concomitant mementine in mild-to-moderate Alzheimerʼs disease. A post hoc analysis. Curr Med Res Opin. 2010; 26: 263-9

53) Mangialasche F, Solomon A, Winblad B, et al. Alzheimerʼs disease: clinical trials and drug development. Lancet Neurol. 2010; 9: 702-16

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp